Evaluation of Efficacy and Prognosis Analysis of Stage III-IV SMARCA4-deficient
Non-small Cell Lung Cancer Treated by PD-1 Immune Checkpoint Inhibitors plus
Chemotherapy and Chemotherapy.
10.3779/j.issn.1009-3419.2023.101.26
- Author:
Xinjuan WANG
1
;
Meng TU
1
;
Hongxia JIA
1
;
Hongping LIU
1
;
Yan WANG
1
;
Yibo WANG
1
;
Nan JIANG
1
;
Chunya LU
1
;
Guojun ZHANG
1
Author Information
1. Department of Pulmonary Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
- Publication Type:Journal Article
- Keywords:
Chemotherapy;
Cox proportional hazards models;
Immune checkpoint inhibitors;
Lung neoplasms;
Prognosis;
SMARCA4
- MeSH:
Humans;
Male;
Carcinoma, Non-Small-Cell Lung/genetics*;
Lung Neoplasms/genetics*;
Immune Checkpoint Inhibitors/therapeutic use*;
Programmed Cell Death 1 Receptor/genetics*;
Retrospective Studies;
Antineoplastic Agents, Immunological/therapeutic use*;
Prognosis;
DNA Helicases/genetics*;
Nuclear Proteins/genetics*;
Transcription Factors/genetics*
- From:
Chinese Journal of Lung Cancer
2023;26(9):659-668
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:The SMARCA4 mutation has been shown to account for at least 10% of non-small cell lung cancer (NSCLC). In the present, conventional radiotherapy and targeted therapy are difficult to improve outcomes due to the highly aggressive and refractory nature of SMARCA4-deficient NSCLC (SMARCA4-DNSCLC) and the absence of sensitive site mutations for targeted drug therapy, and chemotherapy combined with or without immunotherapy is the main treatment. Effective SMARCA4-DNSCLC therapeutic options, however, are still debatable. Our study aimed to investigate the efficacy and prognosis of programmed cell death 1 (PD-1) immune checkpoint inhibitors (ICIs) in combination with chemotherapy and chemotherapy in patients with stage III-IV SMARCA4-DNSCLC.
METHODS:46 patients with stage III-IV SMARCA4-DNSCLC were divided into two groups based on their treatment regimen: the chemotherapy group and the PD-1 ICIs plus chemotherapy group, and their clinical data were retrospectively analyzed. Efficacy assessment and survival analysis were performed in both groups, and the influencing factors for prognosis were explored for patients with SMARCA4-DNSCLC.
RESULTS:Male smokers are more likely to develop SMARCA4-DNSCLC. There was no significant difference in the objective response rate (76.5% vs 69.0%, P=0.836) between chemotherapy and the PD-1 ICIs plus chemotherapy or the disease control rate (100.0% vs 89.7%, P=0.286). The one-year overall survival rate in the group with PD-1 ICIs plus chemotherapy was 62.7%, and that of the chemotherapy group was 46.0%. The difference in median progression-free survival (PFS) between the PD-1 ICIs plus chemotherapy group and the chemotherapy group was statistically significant (9.3 mon vs 6.1 mon, P=0.048). The results of Cox regression analysis showed that treatment regimen and smoking history were independent influencing factors of PFS in patients with stage III-IV SMARCA4-DNSCLC, and family history was an individual influencing factor of overall survival in patients with stage III-IV SMARCA4-DNSCLC.
CONCLUSIONS:Treatment regimen may be a prognostic factor for patients with SMARCA4-DNSCLC, and patients with PD-1 ICIs plus chemotherapy may have a better prognosis.
